• Tackling real-world challenges in securing early access for rare disease patients through named patient programmes across diverse European healthcare systems

• Exploring country-specific regulatory nuances and their impact on rare disease access pathways

• Gaining practical insights and strategies for coordinating named patient programmes, overcoming cross-jurisdictional hurdles and ensuring patient access